Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Farmacia Hospitalaria
versão On-line ISSN 2171-8695versão impressa ISSN 1130-6343
Resumo
MURGADELLA-SANCHO, Anna et al. Experience in the use of remdesivir in patients with SARS-CoV-2 pneumonia. Farm Hosp. [online]. 2021, vol.45, n.5, pp.253-257. Epub 16-Jan-2023. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.11692.
Objective:
To describe the effectiveness and safety of remdesivir in patients with SARS-CoV-2 pneumonia in real-world clinical practice conditions.
Method:
Retrospective observational study that included all adults with SARS-CoV-2 pneumonia admitted at the Moisès Broggi Hospital and treated with remdesivir between July 1st and November 7th, 2020. Efficacy outcomes were time to recovery, 28-day mortality, length of hospital stay, and the need of mechanical ventilation after treatment. The main safetyrelated endpoint was elevation of transaminases after treatment.
Results:
A total of 111 patients were included of whom 97 (87.4%) were receiving low-flow oxygen therapy. Median time to recovery was 9 days [6-14]. Seven patients (6.3%) died at 28 days’ follow-up. Median length of hospital stay was 12 days [9-22] and 15 patients (13.5%) needed mechanical ventilation after treatment with remdesivir. Severe hypertransaminasemia was observed in 4 patients (4%).
Conclusions:
Clinical outcomes of patients with SARS-CoV-2 pneumonia on low-flow oxygen therapy treated with remdesivir were similar to those published in clinical trials, both in terms of time to recovery and 28-day mortality.
Palavras-chave : SARS-CoV-2; Pneumonia; Remdesivir; Adults; Antivirals.